-transparent.png){kind=logo}
The antihypertensive effect of twice-daily administration of verapamil hydrochloride was evaluated in 21 adult patients with mild to moderate essential hypertension. Following four weeks of placebo therapy, verapamil was given for four weeks with a treatment goal of sitting diastolic blood pressure (BP) of less than 90 mm Hg, or to a maximum dose of 160 mg twice daily. Sitting and standing BPs, heart rate, and verapamil plasma levels were determined weekly, ten to 12 hours post dose. At the maximal dose (mean, 154 +/- 19.2 mg), heart rate was not affected, side effects were minimal, and sitting diastolic BP was significantly reduced from placebo baseline, with 12 of 21 patients having a fall in sitting diastolic BP of 10 mm Hg or more or less than 90 mm Hg. A trough verapamil plasma level of greater than 80 ng/mL was associated with a good hypotensive response. These data indicate the safety and utility of twice-daily verapamil administration for the treatment of essential hypertension and suggest the value of obtaining verapamil plasma levels as a guide to dosage determination.
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
January 1988,
Annals of clinical research,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
September 1986,
Journal of clinical hypertension,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
February 1986,
The American journal of cardiology,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
May 1978,
Journal of the Tennessee Medical Association,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
June 1979,
European journal of clinical pharmacology,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
September 1971,
Lancet (London, England),
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
May 2004,
British journal of clinical pharmacology,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
April 1996,
Controlled clinical trials,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
November 1980,
Clinical pharmacology and therapeutics,
W Frishman, and
S Charlap, and
B Kimmel, and
S Saltzberg, and
J Stroh, and
P Weinberg, and
E Monuszko, and
J Wiezner, and
F Dorsa, and
S Pollack
April 1976,
Annals of clinical research,
